The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914352/
Rationale: Primary central nervous system diffuse large B-cell lymphoma (PCNSL) is a rare and aggressive entity that resides in an immune-privileged site. The tumor microenvironment (TME) and the disruption of...
-
Mark Fesler4yrWow. Very complex article dividing pcnsl into subgroups based on a multifaceted immune signature that may have important prognostic and therapeutic implications if confirmed
Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist - Katrin Schmittlutz, Reinhard Marks, 2021
Source : https://journals.sagepub.com/doi/full/10.1177/2040620721996484
Abstract Treatment decisions for aggressive non-Hodgkin lymphoma in elderly and frail patients still remain challenging. The heterogeneity of elderly patients consists of various physical and psychological states, coexisting comorbidities as...
-
Mark Fesler4yrThis is a nice review on elderly dlbcl. It seems likely that with newer less toxic therapies and better categorization of elderly patients into functional categories that we will Show More
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33202794/
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line...
-
Mark Fesler4yrIt’s exciting how many supposedly non cross resistant targets we are identifying for this disease including cd19 and cd79 in addition to cd20. These therapies with various mechanisms of Show More
Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33789222/
1 Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran. 2 Department of Medical Genetics, Iran University of Medical Sciences (IUMS), Tehran, Iran; Medical Genetics...
-
Mark Fesler4yrWhat will come to the clinic faster ....effective NK car therapy with reduced toxicities or car T cells with reduced toxicity with off switches as this article describes ?
Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33787861/
1 Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Université de Rennes, Établissement Français du Sang de Bretagne, INSERM, Rennes, France. 2 Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Rennes, France. 3 INSERM UMR...
-
Mark Fesler4yrInteresting kind of research. Will be interesting to see if the findings from this study can be translated to improved T cell mediated anti lymphoma therapeutics in the future